[144] Axsome Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Axsome Therapeutics (AXSM) Form 144 notice reports proposed sale of 20,000 common shares through Charles Schwab & Co., with an aggregate market value of $2,446,052.00 and an approximate sale date of 08/27/2025. The issuer has 49,901,487 shares outstanding. The shares being offered were acquired by exercise on 03/15/2017 (3,298 shares) and 03/29/2017 (16,702 shares), paid in cash to Axsome Therapeutics, Inc.

The filing also discloses prior sales by the same account in the past three months: 08/22/2025 sale of 16,694 shares for $2,004,598.00 and 08/26/2025 sale of 20,000 shares for $2,400,658.00, seller address listed as Roger Jeffs at One World Trade Center, New York.

Positive

• Required disclosure provided: Form 144 supplies acquisition dates, broker, number of shares, and aggregate market value, supporting regulatory transparency.
• Use of regulated broker: Proposed sale routed through Charles Schwab & Co., indicating an established execution channel.

Negative

• Significant insider liquidity: Recent and proposed sales total 56,694 shares sold or to be sold within a short period, representing notable insider disposals.
• Large gross proceeds: Recent disposals generated approximately $4.4 million and the proposed sale is about $2.45 million, which may be material to investor perception of insider confidence.

Insights

Securities/Equity Analyst

TL;DR: Insider lock-up sales totaling 56,694 shares recently and a proposed 20,000-share sale signal notable insider liquidity but no new issuer disclosures.

The Form 144 documents planned and recent sales by the account holder rather than any corporate action by Axsome. The proposed 20,000-share sale of common stock, valued at about $2.45 million, follows two recent dispositions totaling 36,694 shares generating roughly $4.4 million in gross proceeds. These transactions reflect insider liquidity events; there is no indication in this filing of material nonpublic information or company-initiated transactions.

Corporate Governance Expert

TL;DR: Multiple Form 144 filings show compliance with disclosure rules for proposed insider sales but raise governance transparency questions investors monitor.

The filing provides required details: acquisition dates, nature of acquisition (exercise and hold), broker, and recent sales. It confirms the signer represents no undisclosed material adverse information. From a governance standpoint, repeated sizable sales by an insider or affiliated person warrant investor attention to ownership trends, though the form itself does not allege any governance breach.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20000	2446052.00	49901487	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2017	Exercise and Hold	Axsome Therapeutics, Inc.			3298	03/15/2017	Cash
Common	03/29/2017	Exercise and Hold	Axsome Therapeutics, Inc.			16702	03/29/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/22/2025	16694	2004598.00
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/26/2025	20000	2400658.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for AXSM disclose?

It discloses a proposed sale of 20,000 common shares (aggregate market value $2,446,052) via Charles Schwab with an approximate sale date of 08/27/2025, plus recent sales on 08/22/2025 and 08/26/2025.

How many Axsome Therapeutics (AXSM) shares are outstanding per the filing?

49,901,487 shares outstanding as stated in the Form 144 securities table.

When and how were the shares being sold acquired?

Shares were acquired by exercise and hold on 03/15/2017 (3,298 shares) and 03/29/2017 (16,702 shares), with payment in cash to Axsome Therapeutics, Inc.

Who acted as broker for the proposed sale in the Form 144?

Charles Schwab & Co., Inc. at 3000 Schwab Way, Westlake, TX 76262 is listed as the broker for the 20,000-share proposed sale.

What recent AXSM sales by the same account are reported in the filing?

08/22/2025: 16,694 shares for $2,004,598.00 and 08/26/2025: 20,000 shares for $2,400,658.00, seller address listed as Roger Jeffs, One World Trade Center, NY.